Stock Price, News, Quote and Profile of PERSONALIS INC(NASDAQ:PSNL) stock

PERSONALIS INC

NASDAQ:PSNL (12/20/2024, 12:13:44 PM)

6.9

+1.64 (+31.18%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

GICS SubIndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-33.33%

Sales Q2Q%40.89%

CRS98

6 Month331.15%

Overview

Earnings (Last)11-06 2024-11-06/amc

Earnings (Next)N/A N/A

Ins Owners19.92%

Inst Owners41.36%

Market Cap487.49M

Shares70.65M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts81.67

Short Float %5.59%

Short Ratio4.36

IPO06-20 2019-06-20

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 223 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.